Multiple Complement Pathway-related Proteins Might Regulate Immunopathogenesis of Major Depressive Disorder
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Objective: Exacerbated inflammatory pathway has emerged as a predominant etiological construct of major depressive disorder (MDD). Innate immune molecules like complement proteins induce inflammatory responses and also regulate key neurobiological processes. However, there is a dearth of literature on the impact of critical complement proteins in MDD. Herein, plasma profiling of seven complement proteins was carried out to obtain a better insight into the role of the complement pathway in MDD. Methods: Plasma levels of C1q, C3, C3b/iC3b, C4, Factor B, Factor H, and properdin were assayed in 22 patients with MDD and 27 healthy controls by multiplex suspension assay. The patients with MDD were diagnosed as per DSM IV-TR. Hamilton Depression Rating Scale (HAM-D), Montgomery Depression Rating Scale and Clinical Global Improvement were used for clinical assessments of the patients. The plasma levels of these complement proteins were also correlated with various clinical scores and phenotypes of MDD. Results: The patients with MDD and healthy controls did not differ in terms of age and gender (p ＞ 0.1). The patients with MDD had a mean duration of illness of around 3 years, with average number of depressive episodes being 6 and the mean HAM-D score was 19. Of the seven complement components, the plasma levels of C1q, Factor B, and Factor H (p ≤ 0.05) were significantly elevated in MDD patients compared to healthy controls. However, the plasma levels of these complement proteins were not found to correlate with the clinical profile of MDD patients. Conclusion: Both Factor B and Factor H are crucial in the induction and regulation of the alternative pathway of complement activation. The alternative pathway also plays a critical role in inflammation. These findings suggest an important role of the alternative complement pathway in immuno-inflammation in MDD.
Abstract
Objective: Exacerbated inflammatory pathway has emerged as a predominant etiological construct of major depressive disorder (MDD). Innate immune molecules like complement proteins induce inflammatory responses and also regulate key neurobiological processes. However, there is a dearth of literature on the impact of critical complement proteins in MDD. Herein, plasma profiling of seven complement proteins was carried out to obtain a better insight into the role of the complement pathway in MDD. Methods: Plasma levels of C1q, C3, C3b/iC3b, C4, Factor B, Factor H, and properdin were assayed in 22 patients with MDD and 27 healthy controls by multiplex suspension assay. The patients with MDD were diagnosed as per DSM IV-TR. Hamilton Depression Rating Scale (HAM-D), Montgomery Depression Rating Scale and Clinical Global Improvement were used for clinical assessments of the patients. The plasma levels of these complement proteins were also correlated with various clinical scores and phenotypes of MDD. Results: The patients with MDD and healthy controls did not differ in terms of age and gender (p ＞ 0.1). The patients with MDD had a mean duration of illness of around 3 years, with average number of depressive episodes being 6 and the mean HAM-D score was 19. Of the seven complement components, the plasma levels of C1q, Factor B, and Factor H (p ≤ 0.05) were significantly elevated in MDD patients compared to healthy controls. However, the plasma levels of these complement proteins were not found to correlate with the clinical profile of MDD patients. Conclusion: Both Factor B and Factor H are crucial in the induction and regulation of the alternative pathway of complement activation. The alternative pathway also plays a critical role in inflammation. These findings suggest an important role of the alternative complement pathway in immuno-inflammation in MDD.
참고문헌 (35)
- Greer TL, "Defining and measuring functional recovery from depression", CNS Drugs, 24, pp.267~284 (2010)
- Gautham MS, "The National Mental Health Survey of India(2016) : prevalence, socio-demographic correlates and treatment gap of mental morbidity", Int J Soc Psychiatry, 66, pp.361~372 (2020)
- Beurel E, "The bidirectional relationship of depression and inflammation : double trouble", Neuron, 107, pp.234~256 (2020)
- Ronovsky M, "Animal models of maternal immune activation in depression research", Curr Neuropharmacol, 14, pp.688~704 (2016)
- Dowlati Y, "A meta-analysis of cytokines in major depression", Biol Psychiatry, 67, pp.446~457 (2010)
- Rizavi HS, "Abnormal gene expression of proinflammatory cytokines and their membrane-bound receptors in the lymphocytes of depressed patients", Psychiatry Res, 240, pp.314~320 (2016)
- Miller AH, "Inflammation and its discontents : the role of cytokines in the pathophysiology of major depression", Biol Psychiatry, 65, pp.732~741 (2009)
- Druart M, "Emerging roles of complement in psychiatric disorders", Front Psychiatry, 10, pp.573~ (2019)
- Coulthard LG, "Complement : the emerging architect of the developing brain", Trends Neurosci, 41, pp.373~384 (2018)
- Fatoba O, "Complement cascade functions during brain development and neurodegeneration", FEBS J, 289, pp.2085~2109 (2022)
- Stevens B, "The classical complement cascade mediates CNS synapse elimination", Cell, 131, pp.1164~1178 (2007)
- Orsini F, "Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis", Front Cell Neurosci, 8, pp.380~ (2014)
- Stephan AH, "The complement system : an unexpected role in synaptic pruning during development and disease", Annu Rev Neurosci, 35, pp.369~389 (2012)
- Föcking M, "Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study : evidence for a role of stress", Mol Psychiatry, 26, pp.524~533 (2021)
- Kopczynska M, "Complement system biomarkers in first episode psychosis", Schizophr Res, 204, pp.16~22 (2019)
- Reginia A, "Assessment of complement cascade components in patients with bipolar disorder", Front Psychiatry, 9, pp.614~ (2018)
- Ishii T, "Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia", Biochem Biophys Res Commun, 497, pp.683~688 (2018)
- Yao Q, "Increased serum levels of complement C1q in major depressive disorder", J Psychosom Res, 133, pp.110105~ (2020)
- Wei J, "Plasma complement component 4 increases in patients with major depressive disorder", Neuropsychiatr Dis Treat, 14, pp.37~41 (2017)
- Yang J, "Is serum complement C1q related to major depressive disorder?", Indian J Psychiatry, 62, pp.659~663 (2020)
- Shin C, "Increased plasma complement factor H is associated with geriatric depression", Int Psychogeriatr, 31, pp.101~108 (2019)
- Tang W, "Inflammatory cytokines, complement factor H and anhedonia in drug-naïve major depressive disorder", Brain Behav Immun, 95, pp.238~244 (2021)
- Zhang C, "Complement factor H and susceptibility to major depressive disorder in Han Chinese", Br J Psychiatry, 208, pp.446~452 (2016)
- Solmi M, "Age at onset of mental disorders worldwide : large-scale meta-analysis of 192 epidemiological studies", Mol Psychiatry, 27, pp.281~295 (2022)
- Otte C, "Major depressive disorder", Nat Rev Dis Primers, 2, pp.16065~ (2016)
- Crider A, "Complement component 3a receptor deficiency attenuates chronic stress-induced monocyte infiltration and depressivelike behavior", Brain Behav Immun, 70, pp.246~256 (2018)
- Presumey J, "Complement system in neural synapse elimination in development and disease", Adv Immunol, 135, pp.53~79 (2017)
- Duman RS, "Synaptic dysfunction in depression : potential therapeutic targets", Science, 338, pp.68~72 (2012)
- Vastag M, "Endothelial cells cultured from human brain microvessels produce complement proteins factor H, factor B, C1 inhibitor, and C4", Immunobiology, 199, pp.5~13 (1998)
- Banda NK, "Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis", J Immunol, 177, pp.1904~1912 (2006)
- Taube C, "Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation", Proc Natl Acad Sci U S A, 103, pp.8084~8089 (2006)
- Ingram G, "Complement regulator factor H as a serum biomarker of multiple sclerosis disease state", Brain, 133(Pt 6), pp.1602~1611 (2010)
- Hye A, "Proteome-based plasma biomarkers for Alzheimer’s disease", Brain, 129(Pt 11), pp.3042~3050 (2006)
- Oksjoki R, "Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions : implications for local regulation of complement activation", Arterioscler Thromb Vasc Biol, 23, pp.630~636 (2003)
- Scholl HP, , PLoS One, 3, pp.e2593~ (2008)